Clinical‐stage natural psychedelic drug development company, Filament Health (NEOE:FH:CA) (OTCQB:FLHLF) expects to complete the financing for net proceeds of approximately C$0.9M.

The company also announced that it intends to delist its common shares voluntarily from Cboe Canada, after obtaining necessary shareholder approval.

Pursuant to the financing, the company will issue a unit comprised of a secured convertible debenture of the company and a warrant for the purchase of common shares of the company.